Affordable Access

deepdyve-link
Publisher Website

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study

Authors
  • Spinner, Christoph D1
  • Kümmerle, Tim2
  • Schneider, Jochen1
  • Cordes, Christiane2
  • Heiken, Hans2
  • Stellbrink, Hans-Jürgen3
  • Krznaric, Ivanka4
  • Scholten, Stephan5
  • Jensen, Björn6
  • Wyen, Christoph2, 7
  • Viehweger, Marin2
  • Lehmann, Clara7
  • Sprinzl, Martin8
  • Stoehr, Albrecht9
  • Bickel, Markus10
  • Jessen, Heiko11
  • Obst, Wilfried12
  • Spornraft-Ragaller, Petra13
  • Khaykin, Pavel14
  • Wolf, Eva15
  • And 30 more
  • 1 Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Germany , (Germany)
  • 2 Private Practice, Germany , (Germany)
  • 3 ICH Study Center, Germany , (Germany)
  • 4 Private Practice, Zentrum für Infektiologie Prenzlauer Berg, Germany , (Germany)
  • 5 Private Practice, Hohenstaufenring, Germany , (Germany)
  • 6 University Hospital Düsseldorf, Germany , (Germany)
  • 7 Department of Internal Medicine I, University Hospital Cologne, Germany , (Germany)
  • 8 Department of Medicine I, University Hospital Mainz, Germany , (Germany)
  • 9 Private Practice, IfI Institute, Germany , (Germany)
  • 10 Private Practice, Infektiologiukum, Germany , (Germany)
  • 11 Private Practice, Jessen2, Germany , (Germany)
  • 12 Department of Gastroenterology, University Hospital Magdeburg, Germany , (Germany)
  • 13 University Hospital Dresden, Germany , (Germany)
  • 14 Private Practice, MainFachArzt, Germany , (Germany)
  • 15 MUC Research Clinical Research Organization (CRO), Germany , (Germany)
  • 16 Bonn University Hospital, Germany , (Germany)
Type
Published Article
Journal
Open Forum Infectious Diseases
Publisher
Oxford University Press
Publication Date
Aug 13, 2020
Volume
7
Issue
9
Identifiers
DOI: 10.1093/ofid/ofaa356
PMID: 32965277
PMCID: PMC7491710
Source
PubMed Central
Keywords
Disciplines
  • AcademicSubjects/MED00290
License
Unknown

Abstract

The DUALIS phase-III study demonstrated non-inferiority of an effective and safe switch to dolutegravir combined with boosted darunavir (2DR) in suppressed people living with HIV as compared to continue 2 nucleoside reverse transcriptase inhibitors in combination with boosted darunavir (3DR).

Report this publication

Statistics

Seen <100 times